Skip to Content

Sanara MedTech Inc SMTI

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Sanara MedTech Inc is a provider of the patented CellerateRX Activated Collagen product in the wound care and surgical markets. The company's primary focus is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics, and post-acute care settings. Its products are primarily sold in the North American advanced wound care and surgical tissue repair markets. It distributes CellerateRX Surgical Activated Collagen Adjuvant; HYCOL Hydrolyzed Collagen; BIAKOS Antimicrobial Skin and Wound Cleanser; and PULSAR II Advanced Wound Irrigation System.

Contact
1200 Summit Avenue, Suite 414
Fort Worth, TX, 76102
T +1 817 529-2300
Sector Healthcare
Industry Medical Care Facilities
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 38